• Home
  • NEW DAY MEDICINE
  • 6 (38) 2021
  • 54 -6 (38) 2021 — Saidova Muxabbat Muxidinovna — DIAGNOSTIC SIGNIFICANCE OF IMC DETERMINATION FOR ASSESSMENT OF ATHEROSCLEROTIC DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS

54 -6 (38) 2021 — Saidova Muxabbat Muxidinovna — DIAGNOSTIC SIGNIFICANCE OF IMC DETERMINATION FOR ASSESSMENT OF ATHEROSCLEROTIC DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS

DIAGNOSTIC SIGNIFICANCE OF IMC DETERMINATION FOR ASSESSMENT OF ATHEROSCLEROTIC DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS

Saidova Muxabbat Muxidinovna Bukhara State Medical Institute

Resume

Cardiovascular disease (CVD) is one of the leading causes of death and disability worldwide. According to the European Society of Cardiology, “… more than 4 million people die from CVD every year, of which 1.4 million are younger 75 years, which is 45% of all deaths … “. According to large research centers, mortality from cardiovascular disease (CVD) is more common in patients with rheumatoid arthritis (RA) than in the general population.

The immediate cause of death in RA patients is diseases associated with atherosclerotic vascular lesions, in particular: ischemic heart disease, acute circulatory disorders in the brain, heart failure.

Key words: rheumatoid arthritis, cardiovascular risk, atherosclerosis, Doppler ultrasonography.

First page

307

Last page

310

For citation: Saidova Muxabbat Muxidinovna DIAGNOSTIC SIGNIFICANCE OF IMC DETERMINATION FOR ASSESSMENT OF ATHEROSCLEROTIC DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS //New Day in Medicine 6(38)2021 307-310 https://cutt.ly/9UCuoGO

LIST OF REFERENCES:

  1. Agca R., Heslinga S.C., Rollefstad S. (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of infl ammatory joint
  2. disorders: 2015/2016 update. Ann Rheum Dis., 76 (1), pp. 17–28.
  3. Piepoli M.F, Hoes A.W, Agewall S, Albus C, Brotons C. (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and byinvited experts). Europ Heart J, 37(29), pp. 2315–2381.
  4. Arida A., Protogerou A.D., Kitas G.D., Sfi kakis P.P. (2018) Systemic Infl ammatory Response and Atherosclerosis: The Paradigm of Chronic Infl ammatory Rheumatic Diseases. Int J Mol Sci., 19 (7),p. 1890.
  5. Francula-Zaninovic S., Nola I.A. (2018) Management of Measurable Variable Cardiovascular Disease Risk Factors. Curr Cardiol Rev., 14 (3), pp. 153–163.
  6. Cooney M.T, Vartiainen E, Laatikainen T, De Bacquer D, McGorrian C.(2012) Cardiovascular risk age: concepts and practicalities. Heart, 98, pp. 941–946.
  7. England B.R., Thiele G.M., Anderson D.R. Mikuls T.R. (2018) Increased cardiovascular risk inrheumatoid arthritis: mechanisms and implications. BMJ, 23, p. 361.
  8. Berger J.S., Jordan C.O., Lloyd-Jones D., Blumenthal R.S.(2010) Screening for Cardiovascular Risk in Asymptomatic Patients //J Am Coll Cardiol, 55, pp. 1169–77.
  9. Karmali K.N., Persell S.D., Perel P. (2017) Risk scoring for the primary prevention of cardiovascular disease. //Cochrane Database of Systematic Reviews, issue 3. Art. No.: CD00688.
  10. Kamilova U.K, Saidova M.M.(2019) Assessment of Cardiovascular Risk in Patients with Rheumatoid Arthritis //Journal of “Cardiology in Belarus”, 2019, volume 11, № 4, pp. 614–619
  11. Willis A., Davies M., Yates T., Khunti K. (2012) Primary prevention of cardiovascular disease using validated risk scores: a systematic review. //Journal of Royal Society of Medicine, 105 (8), pp. 348–56.
  12. Crowson C.S., Gabriel Sh.E., Semb A.G. (2018) Rheumatoid arthritis-specifi c cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. //Swiss Med Wkl, 22, p. 148.

file

download